Start Submission Become a Reviewer

Reading: Temozolomide in treatment resistant prolactinomas


A- A+
Alt. Display

Case Reports

Temozolomide in treatment resistant prolactinomas


V. N. Shree ,

Hospital Putrajaya, MY
X close

L. B. Mohamed Badrulnizam

Hospital Putrajaya, MY
X close


We report a case of a 23-year-old gentleman, diagnosed with macroprolactinoma at age 14. He presented with bitemporal hemianopia and no other symptoms of prolactinoma. He underwent two trans-sphenoidal surgeries and subsequently developed panhypopituitarism requiring replacement therapy. Despite compliance and up titrated doses of cabergoline (maximum total dose of 12mg/week), resistant prolactin (PRL) levels up to 22614mU/L were noted. Trial of temozolomide combined with cabergoline showed prolactin levels that drastically declined over 16 weeks and remained stable at 52 weeks with significant radiological remission.
How to Cite: Shree, V.N. and Badrulnizam, L.B.M., 2018. Temozolomide in treatment resistant prolactinomas. Sri Lanka Journal of Diabetes Endocrinology and Metabolism, 8(2), pp.39–42. DOI:
Published on 29 Aug 2018.
Peer Reviewed


  • PDF (EN)

    comments powered by Disqus